Quick Answer
FILANA THERAPEUTICS, INC. reported Operating Income Loss of -$95.39 million for the year ending 2025.
- FILANA THERAPEUTICS, INC. showed an increase of +32.6% in Operating Income Loss from 2024 to 2025.
- This data is from FILANA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), FILANA THERAPEUTICS, INC.'s Operating Income Loss has declined by 1,312.3%.
- Historical annual values: Fiscal year 2025: -$95.39 million | Fiscal year 2024: -$141.45 million | Fiscal year 2023: -$105.96 million | Fiscal year 2022: -$80.02 million | Fiscal year 2021: -$32.87 million | Fiscal year 2020: -$6.45 million | Fiscal year 2019: -$4.96 million | Fiscal year 2018: -$6.66 million | Fiscal year 2017: -$11.95 million | Fiscal year 2016: -$14.96 million | Fiscal year 2015: -$14.20 million | Fiscal year 2014: -$12.43 million | Fiscal year 2013: $31.37 million | Fiscal year 2012: -$3.90 million | Fiscal year 2011: -$3.51 million | Fiscal year 2010: -$13.70 million | Fiscal year 2009: -$6.75 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: